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Transmission of HIV-1 by breastfeeding is responsible for
at least 250,000 yearly acquired HIV-1 paediatric infec-
tions worldwide. However, it remains largely out of reach
of short perinatal prophylactic regimens. All HIV-1
infected women eligible for highly active antiretroviral
therapy (HAART), lactating or not, should be offered
treatment for their own health, which will also reduce
transmission to their babies. Recent studies suggest that
residual transmission can occur through HIV-1 cellular
reservoirs in breast milk of these women despite success-
ful HAART. Prevention of breastfeeding transmission of
HIV-1 from women non eligible for HAART remains a
dilemma. Prophylactic maternal HAART restricted to the
lactation period is an option. Peri-exposure prophylaxis
(PEP) consisting in the administration of an antiretroviral
(ARV) drug to the infant during exposure to HIV-1
through breastfeeding as a prophylaxis, is another option.
Proof of concept studies (two randomised trials, PEPI in
Malawi and SWEN in Uganda, Ethiopia, India as well as
the observational cohort MITRA in Tanzania) have con-
firmed the efficacy of PEP in preventing transmission.
Infant PEP regimen included nevirapine (NVP) for 6
weeks in SWEN, NVP or NVP plus zidovudine for 14
weeks in PEPI, and lamivudine for 6 months in MITRA.
Part of the preventive benefit of infant PEP was lost if the
babies were still breastfed and exposed to HIV-1 after
prophylaxis was stopped. PEP regimens were associated
with minimal side effects, but in the SWEN study, PEP
failure was associated with a very high rate of NVP resist-
ance in babies, which may challenge the first-line HAART
regimen recommended as soon as infant HIV infection is
diagnosed. PEP offers the potential advantages of sparing
ARV exposure in women non eligible for HAART (avoid-
ance of side effects and of selection of resistance), of being
independent of HIV-1 reservoirs in breast milk, of being
potentially cheap and easy to administer, and of allowing
the promotion of optimal infant feeding practices to all
women, regardless of their HIV status. These advantages
have to be balanced with the risk of developing side effects
in uninfected babies during extended exposure to the PEP
drug and of selecting ARV drug resistant viruses in babies
who acquire HIV-1 despite prophylaxis. PEP is a promis-
ing intervention to prevent breastfeeding transmission of
HIV-1. More research is needed to identify the PEP drug
regimen having the optimal benefit/risk ratio (including
long acting drugs) and to synergise PEP with promotion
of best practices of infant feeding.
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